Add to ORKGProtein aggregation is a major concern during monoclonal antibody (mAb) production [1,2]. The presence of aggre-gates can reduce the therapeutic efficacy of mAbs and trig-ger immunogenic responses upon administration [3]
Aggregation has been identified as one of the major degradation pathways that affect the quality and...
Aggregation of therapeutic antibodies could be generated at different steps of the manufacturing pro...
Therapeutic antibodies have the potential to induce immunogenicity leading to the development of ant...
Protein aggregates represent a safety, immunological and stability concern in therapeutic protein fo...
apeutics in the treatment of various diseases [1]. During manufacturing of mAbs higher molecular wei...
Monoclonal antibodies (mAbs) are successful biopharmaceuticals playing an important role in the trea...
<p>Preparations of MB-435- α6HG6 cells were continuously infused with either of two anti-integrin mA...
One of the dominant classes of protein based drugs, which continues to contribute to the growth and ...
Aggregates in protein therapeutics like IgG monoclonal antibodies (mAb) are detrimental to product s...
Therapeutic proteins have become invaluable in treating a wide range of serious and life-threatening...
Monoclonal antibody (MAb) production using immobilized hybridoma cells and free cells were compared ...
Establishing an appropriate formulation is a crucial step in development of therapeutic monoclonal a...
The elicitation of anti-drug antibodies (ADA) against biotherapeutics can have detrimental effects o...
The effect of serum on cell growth and monoclonal antibody (MAb) productivity was studied in a repea...
Subvisible proteinaceous particles which are present in all therapeutic protein formulations are in ...
Aggregation has been identified as one of the major degradation pathways that affect the quality and...
Aggregation of therapeutic antibodies could be generated at different steps of the manufacturing pro...
Therapeutic antibodies have the potential to induce immunogenicity leading to the development of ant...
Protein aggregates represent a safety, immunological and stability concern in therapeutic protein fo...
apeutics in the treatment of various diseases [1]. During manufacturing of mAbs higher molecular wei...
Monoclonal antibodies (mAbs) are successful biopharmaceuticals playing an important role in the trea...
<p>Preparations of MB-435- α6HG6 cells were continuously infused with either of two anti-integrin mA...
One of the dominant classes of protein based drugs, which continues to contribute to the growth and ...
Aggregates in protein therapeutics like IgG monoclonal antibodies (mAb) are detrimental to product s...
Therapeutic proteins have become invaluable in treating a wide range of serious and life-threatening...
Monoclonal antibody (MAb) production using immobilized hybridoma cells and free cells were compared ...
Establishing an appropriate formulation is a crucial step in development of therapeutic monoclonal a...
The elicitation of anti-drug antibodies (ADA) against biotherapeutics can have detrimental effects o...
The effect of serum on cell growth and monoclonal antibody (MAb) productivity was studied in a repea...
Subvisible proteinaceous particles which are present in all therapeutic protein formulations are in ...
Aggregation has been identified as one of the major degradation pathways that affect the quality and...
Aggregation of therapeutic antibodies could be generated at different steps of the manufacturing pro...
Therapeutic antibodies have the potential to induce immunogenicity leading to the development of ant...